EXPLORING THE IMPACT OF CERVICAL CANCER: A LOOK AT PREVENTION, DIAGNOSIS, AND THERAPY

Cervical cancer stands as a significant global health concern, ranking as the fourth most common cancer among women worldwide. Despite its preventable nature, it contributes to over 342,000 deaths annually, with approximately 90% of these deaths occurring in low- and middle-income countries (LMICs). Caused primarily by persistent infection with high-risk strains of the Human Papillomavirus (HPV), cervical cancer exemplifies the intersection of virology, immunology, public health, and gender equity. Advances in preventive medicine—including HPV vaccination and cervical screening—have demonstrated considerable efficacy in reducing disease burden, yet access to these life-saving interventions remains unequally distributed. Cervical cancer progresses slowly, often taking 10–20 years to develop from initial HPV infection to invasive cancer. This prolonged progression provides a valuable window for prevention and early intervention through screening methods like the Pap smear and HPV DNA testing. However, despite this opportunity, awareness levels and health-seeking behavior remain low in many populations due to stigma, misinformation, limited infrastructure, and socioeconomic disparities. Simultaneously, regular screening has emerged as a cornerstone in reducing mortality. Innovations such as self-sampling kits and visual inspection with acetic acid (VIA) have shown promise in improving accessibility, especially in rural or under-resourced regions. Nevertheless, infrastructural barriers, lack of trained professionals, and irregular follow-ups persist as hurdles to effective implementation.